Skip to Content

Utibron Neohaler Approval History

FDA Approved: Yes (First approved October 29, 2015)
Brand name: Utibron Neohaler
Generic name: glycopyrrolate and indacaterol
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: COPD

Utibron Neohaler (glycopyrrolate and indacaterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) fixed-dose combination for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Utibron Neohaler

DateArticle
Oct 29, 2015Approval FDA Approves Utibron Neohaler (indacaterol/glycopyrrolate) for COPD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide